Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 5, 2015, Pages 1157-1164

  Marin, Mona ^a   Yawn, Barbara P ^b   Hales, Craig M ^a   Wollan, Peter C ^b   Bialek, Stephanie R ^a   Zhang, John ^a   Kurland, Marge J ^b   Harpaz, Rafael ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b OLMSTED MEDICAL CENTER   (United States)

Author keywords

Breakthrough zoster; Herpes zoster; PHN; Postherpetic neuralgia; Shingles; Vaccine; Zostavax; Zoster pain; Zoster vaccine

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE DURATION; FEMALE; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN SEVERITY; POSTHERPETIC NEURALGIA; PRODROMAL SYMPTOM; SCORING SYSTEM; VACCINATION; VERY ELDERLY; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; MINNESOTA; NEURALGIA, POSTHERPETIC;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; MINNESOTA; NEURALGIA, POSTHERPETIC;

EID: 84942419784     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1016681     Document Type: Article

References (30)

1. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341-9; PMID:17976353; http://dx.doi.org/10.4065/ 82.11.1341
2. Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc 2009; 84:787-94; PMID:19720776; http://dx. doi.org/10.4065/84.9.787
3. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45:S52-3; PMID:8545021; http://dx.doi.org/10.1212/ WNL.45.12_Suppl_8.S52
4. Di Legami V, Gianino MM, Ciofidegli Atti M, Massari M, Migliardi A, Tomba GS, Zotti C; Zoster Study Group. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine 2007; 25:7598-604; PMID:17889410; http://dx. doi.org/10.1016/j.vaccine.2007.07.049
5. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25:8326-37; PMID:17980938; http://dx.doi.org/10.1016/j. vaccine.2007.09.066
6. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009; 27:520-9; PMID:19027048; http://dx.doi.org/ 10.1016/j.vaccine.2008.11.012
7. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44(Suppl 1):S1-26; PMID:17143845; http://dx. doi.org/10.1086/510206
8. Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis 1999; 28:736-9; PMID:10825029; http://dx.doi.org/10.1086/515205
9. Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother 2013; 9:1177-84; PMID:23324598; http://dx.doi.org/ 10.4161/hv.23491
10. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19:3076-90; PMID:11312002; http://dx.doi.org/ 10.1016/S0264-410X(01)00044-5
11. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45:S41-6; PMID:8545018; http:// dx.doi.org/10.1212/WNL.45.12_Suppl_8.S41
12. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices Centers for Disease C, Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30; quiz CE2-4; PMID:18528318
13. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; http://dx.doi.org/10.1056/NEJMoa051016
14. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988; 10:212-41; PMID:3066628
15. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160-6; PMID:21224457; http://dx.doi.org/ 10.1001/jama.2010.1983
16. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013; 10:e1001420; PMID:23585738; http://dx.doi.org/10.1371/journal. pmed.1001420
17. Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol 2011; 174:1054-61; PMID:21920944; http://dx.doi.org/10.1093/aje/ kwr206
18. Schmader KE, Levin MJ, Gnann JW, Jr., McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8; PMID:22291101; http://dx.doi. org/10.1093/cid/cir970
19. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27:882-7; PMID:19071175; http://dx.doi.org/10.1016/j. vaccine.2008.11.077
20. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23:490-6; PMID:17575488; http://dx.doi.org/10.1097/AJP.0b013e318065b6c9
21. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342-8; PMID:15307000; http://dx.doi.org/ 10.1086/421942
22. Food and Drug Administration. ZOSTAVAX: Statistical Review and Evaluation. 2005. http://wwwfdagov/ ohrms/dockets/ac/05/briefing/5-4198B2_2pdf pages 7-9, accessed 16 June 2014.
23. Williams WW, Lu PJ, O'Halloran A, Bridges CB, Pilishvili T, Hales CM, Markowitz LE; Centers for Disease Control and Prevention (CDC). Noninfluenza vaccination coverage among adults-United States, 2012. MMWR Morb Mortal Wkly Rep 2014; 63:95-102; PMID:24500288
24. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ, 3rd, Pankratz JJ, Brue SM, Rocca WA. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol 2012; 41:1614-24; PMID:23159830; http://dx.doi.org/ 10.1093/ije/dys195
25. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344-56; PMID:15336639; http://dx. doi.org/10.1016/j.jpain.2004.06.001
26. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods. 2002; 2 ed. Thousand Oaks, CA: Sage Publications, Inc; 2002.
27. Dworkin RH, Gnann JW, Jr., Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008; 9:S37-44; PMID:18166464; http://dx.doi.org/10.1016/j.jpain.2007.10.008
28. Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, Camden S, Mansi JA. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010; 26:656-66; PMID:20842005
29. Nadaraya EA. On estimating regression. Theor Probab Appl 1964; 9:141-2; http://dx.doi.org/10.1137/ 1109020
30. Pinheiro J, Bates D, DebRoy S, Sarkar D and R Core Team (2014). Linear and Nonlinear Mixed Effects Models. R package version. 3:1-117, http://CRAN.Rproject. org/package=nlme.